Refractory Tumor Clinical Trial
Official title:
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 in An Enriched Population of Treatment-Refractory Advanced Solid Tumors
This is a phase IIa open-label, non-randomized dose-expansion study of OPB-111077 in patients with advanced, treatment refractory cancers who have biopsy-amenable lesions at study entry.
This is a phase IIa open-label, non-randomized dose-expansion study of OPB-111077 in
patients with advanced, treatment refractory cancers who have biopsy-amenable lesions at
study entry. Patients on the proposed study will be treated with the RPII dose of OPB-111077
(600mg on a 4 days-on, 3 days-off per week schedule). They will be enrolled in two parallel
cohorts: i. patients with tumors predicted to be dependent on oxidative phosphorylation
metabolism or oncogene addicted tumors which have developed resistance to primary TKI
therapy, or ii. patients with nasopharyngeal carcinoma
Each cohort will contain 11-26 patients, over a period of 12-36 months. Subjects will
receive OPB-111077 in 28-day cycles till disease progression or intolerable toxicity.
Mandatory tumour biopsies will be performed at baseline and on cycle 1 day 15 (where
feasible and accessible). Circulating biomarker blood sampling will be performed on days 1,
11 and 15 of cycle 1, and upon completion of OPB-111077 dosing. Pharmacokinetics blood
sampling will be performed on days 11 and 15 of cycle 1. Safety assessments will be
performed on cycle 1 day 1, cycle 1 day 8, cycle 1 day 15, bi-weekly till week 8, then
monthly thereafter and response assessments will be performed every 8 weeks. Metabolic
response assessment by PET/CT will be performed after 2 cycles of treatment, while
radiologic response assessment will be performed after every 2 cycles of OPB-111077 from
cycle 4 onwards.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05099549 -
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
|
Phase 1/Phase 2 | |
| Completed |
NCT06202599 -
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
|
||
| Recruiting |
NCT04900519 -
Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04239092 -
9-ING-41 in Pediatric Patients With Refractory Malignancies.
|
Phase 1 | |
| Withdrawn |
NCT04809012 -
Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT06047860 -
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT05767684 -
Neoantigen Derived DCs as Cancer Treatment
|
Phase 1 | |
| Not yet recruiting |
NCT06456138 -
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03239015 -
Efficacy and Safety of Precision Therapy in Refractory Tumor
|
Phase 2 | |
| Completed |
NCT03415477 -
Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05752552 -
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours
|
Phase 1 | |
| Completed |
NCT02564198 -
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06098651 -
A Study of DCR-STAT3 in Adults With Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05790447 -
Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
|
Phase 2 |